000084692 001__ 84692
000084692 005__ 20200513005826.0
000084692 0247_ $$2doi$$a10.1007/s10620-018-5362-3
000084692 0248_ $$2sideral$$a109098
000084692 037__ $$aART-2018-109098
000084692 041__ $$aeng
000084692 100__ $$aChaparro, M.
000084692 245__ $$aCorrelation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients
000084692 260__ $$c2018
000084692 5060_ $$aAccess copy available to the general public$$fUnrestricted
000084692 5203_ $$aObjectives: (a) To evaluate the diagnostic accuracy of anti-TNF trough levels to predict mucosal healing in inflammatory bowel disease (IBD); (b) to determine the best cut-off point to predict mucosal healing in IBD patients treated with anti-TNF.
Methods: This is a multicenter, prospective study. IBD patients under anti-TNF treatment for at least 6 months that had to undergo an endoscopy were included. Mucosal healing was defined as: Simple endoscopic score for Crohn’s Disease < 3 for Crohn’s disease (CD), Rutgeerts score < i2 for CD in postoperative setting, or Mayo endoscopic score = 1 for ulcerative colitis (UC). Anti-TNF concentrations were measured using SMART ELISAs at trough.
Results: A total of 182 patients were included. Anti-TNF trough levels were significantly higher among patients that had mucosal healing than among those who did not. The area under the curve of infliximab for mucosal healing was 0.63 (best cutoff value 3.4 µg/mL), and for adalimumab 0.60 (best cutoff value 7.2 µg/mL). In the multivariate analysis, having anti-TNF drug levels above the cutoff values [odds ratio (OR) 3.1]) and having UC instead of CD (OR 4) were associated with a higher probability of having mucosal healing. Additionally, the need for an escalated dosage (OR 0.2) and current smoking habit (OR 0.2) were also associated with a lower probability of mucosal healing.
Conclusions: There was an association between anti-TNF trough levels and mucosal healing in IBD patients; however, the accuracy of the determination of infliximab and adalimumab concentrations able to predict mucosal healing was suboptimal.
000084692 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/12-02557$$9info:eu-repo/grantAgreement/ES/ISCIII/PI13-00041$$9info:eu-repo/grantAgreement/ES/MINECO/SAF2014-56642-JIN
000084692 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000084692 590__ $$a2.937$$b2018
000084692 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b48 / 84 = 0.571$$c2018$$dQ3$$eT2
000084692 592__ $$a1.292$$b2018
000084692 593__ $$aPhysiology$$c2018$$dQ1
000084692 593__ $$aGastroenterology$$c2018$$dQ1
000084692 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000084692 700__ $$aBarreiro-de Acosta, M.
000084692 700__ $$aEcharri, A.
000084692 700__ $$aAlmendros, R.
000084692 700__ $$aBarrio, J.
000084692 700__ $$aLlao, J.
000084692 700__ $$0(orcid)0000-0003-0076-3529$$aGomollón, F.$$uUniversidad de Zaragoza
000084692 700__ $$aVera, M.
000084692 700__ $$aCabriada, J.L.
000084692 700__ $$aGuardiola, J.
000084692 700__ $$aGuerra, I.
000084692 700__ $$aBeltrán, B.
000084692 700__ $$aRoncero, O.
000084692 700__ $$aBusquets, D.
000084692 700__ $$aTaxonera, C.
000084692 700__ $$aCalvet, X.
000084692 700__ $$aFerreiro-Iglesias, R.
000084692 700__ $$aOllero Pena, V.
000084692 700__ $$aBernardo, D.
000084692 700__ $$aDonday, M.G.
000084692 700__ $$aGarre, A.
000084692 700__ $$aGodino, A.
000084692 700__ $$aDíaz, A.
000084692 700__ $$aGisbert, J.P.
000084692 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000084692 773__ $$g64, 846 - 854 (2018), 1-9$$pDig. dis. sci.$$tDIGESTIVE DISEASES AND SCIENCES$$x0163-2116
000084692 8564_ $$s601771$$uhttps://zaguan.unizar.es/record/84692/files/texto_completo.pdf$$yPostprint
000084692 8564_ $$s26775$$uhttps://zaguan.unizar.es/record/84692/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000084692 909CO $$ooai:zaguan.unizar.es:84692$$particulos$$pdriver
000084692 951__ $$a2020-05-13-00:51:58
000084692 980__ $$aARTICLE